Kros JM - Search Results

1

Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.

Zhu C, Mustafa D, Zheng PP, van der Weiden M, Sacchetti A, Brandt M, Chrifi I, Tempel D, Leenen PJM, Duncker DJ, Cheng C, Kros JM. Zhu C, et al. Among authors: kros jm. Neuro Oncol. 2017 May 1;19(5):648-659. doi: 10.1093/neuonc/now251. Neuro Oncol. 2017. PMID: 28453746 Free PMC article.

2

Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis.

Kros JM, Zheng P, Dinjens WN, Alers JC. Kros JM, et al. J Neuropathol Exp Neurol. 2002 Sep;61(9):806-14. doi: 10.1093/jnen/61.9.806. J Neuropathol Exp Neurol. 2002. PMID: 12230327

3

Proteomics in primary brain tumors.

Zheng PP, Kros JM, Sillevis-Smitt PA, Luider TM. Zheng PP, et al. Among authors: kros jm. Front Biosci. 2003 Jan 1;8:d451-63. doi: 10.2741/1008. Front Biosci. 2003. PMID: 12456299 Review.

4

Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma.

Kros JM, Bagdi EK, Zheng P, Hop WC, Driesse MJ, Krenacs L, Dinjens WN. Kros JM, et al. J Neurosurg. 2002 Dec;97(6):1390-6. doi: 10.3171/jns.2002.97.6.1390. J Neurosurg. 2002. PMID: 12507138

5

Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors.

Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA, Kros JM. Zheng PP, et al. Among authors: kros jm. J Neuropathol Exp Neurol. 2003 Aug;62(8):855-62. doi: 10.1093/jnen/62.8.855. J Neuropathol Exp Neurol. 2003. PMID: 14503641

6

Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature.

Zheng PP, Sieuwerts AM, Luider TM, van der Weiden M, Sillevis-Smitt PA, Kros JM. Zheng PP, et al. Among authors: kros jm. Am J Pathol. 2004 Jun;164(6):2217-28. doi: 10.1016/S0002-9440(10)63778-9. Am J Pathol. 2004. PMID: 15161654 Free PMC article.

7

Differential expression of Hela-type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells.

Zheng PP, van der Weiden M, Kros JM. Zheng PP, et al. Among authors: kros jm. J Pathol. 2005 Feb;205(3):408-14. doi: 10.1002/path.1700. J Pathol. 2005. PMID: 15682433

8

Low-molecular weight caldesmon as a potential serum marker for glioma.

Zheng PP, Hop WC, Sillevis Smitt PA, van den Bent MJ, Avezaat CJ, Luider TM, Kros JM. Zheng PP, et al. Among authors: kros jm. Clin Cancer Res. 2005 Jun 15;11(12):4388-92. doi: 10.1158/1078-0432.CCR-04-2512. Clin Cancer Res. 2005. PMID: 15958622

9

Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.

Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM. Kurt E, et al. Among authors: kros jm. Cancer. 2006 Jan 15;106(2):388-95. doi: 10.1002/cncr.21608. Cancer. 2006. PMID: 16342252 Free article.

10

Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels.

Mustafa DA, Burgers PC, Dekker LJ, Charif H, Titulaer MK, Smitt PA, Luider TM, Kros JM. Mustafa DA, et al. Among authors: kros jm. Mol Cell Proteomics. 2007 Jul;6(7):1147-57. doi: 10.1074/mcp.M600295-MCP200. Epub 2007 Mar 14. Mol Cell Proteomics. 2007. PMID: 17360931 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

312 results

Search Page